Nasdaq · Biotech stocks database

BSEM — BioStem Technologies Inc.

BSEM (BioStem Technologies Inc.) stock: $4.74, $84.6M market cap, $7.0M cash, $77.6M EV, $156.1M fully diluted market cap. Data from Fully Diluted's biotech stocks database.

Share price

$4.74

Market cap

$84.6M

Cash

$7.0M

Enterprise value

$77.6M

Balance sheet

Cash	$7.0M
Debt	$0.0M
Net cash	$7.0M
Enterprise value	$77.6M
Basic shares	17.8M shares
Fully diluted shares	32.9M shares
Fully diluted market cap	$156.1M
Cash per share	$0.39

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading BSEM daily closes…

Loading price history…

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06811909	Not disclosed	Active, not recruiting	Sponsor	BioStem Technologies	—	Non-infected Venous Leg Ulcer; Venous Leg Ulcer; Venous Insufficiency	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for BioStem Technologies on ClinicalTrials.gov

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.

Subscribe to Compounding Ego